4161 Stock Overview
Bioptik Technology Incorporation engages in the production and sale of medical devices and reagents worldwide.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 5/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Bioptik Technology Incorporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NT$33.60 |
52 Week High | NT$41.48 |
52 Week Low | NT$26.95 |
Beta | 0.30 |
1 Month Change | -9.43% |
3 Month Change | 5.16% |
1 Year Change | 20.62% |
3 Year Change | 20.41% |
5 Year Change | 19.39% |
Change since IPO | -3.99% |
Recent News & Updates
Shareholder Returns
4161 | TW Medical Equipment | TW Market | |
---|---|---|---|
7D | -0.7% | -4.3% | -5.7% |
1Y | 20.6% | 1.9% | 23.8% |
Return vs Industry: 4161 exceeded the TW Medical Equipment industry which returned 1.9% over the past year.
Return vs Market: 4161 underperformed the TW Market which returned 23.8% over the past year.
Price Volatility
4161 volatility | |
---|---|
4161 Average Weekly Movement | 4.9% |
Medical Equipment Industry Average Movement | 4.4% |
Market Average Movement | 4.6% |
10% most volatile stocks in TW Market | 8.5% |
10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 4161 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4161's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | n/a | n/a | www.bioptik.com.tw |
Bioptik Technology Incorporation engages in the production and sale of medical devices and reagents worldwide. It offers EasyMate blood glucose monitoring systems; blood glucose/cholesterol/uric acid monitoring systems and its strips; and hyaluronic acid skin care products. The company also provides skin care products and dietary supplements, as well as biodiesel products.
Bioptik Technology Incorporation Fundamentals Summary
4161 fundamental statistics | |
---|---|
Market cap | NT$1.78b |
Earnings (TTM) | NT$85.71m |
Revenue (TTM) | NT$828.50m |
20.8x
P/E Ratio2.1x
P/S RatioIs 4161 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4161 income statement (TTM) | |
---|---|
Revenue | NT$828.50m |
Cost of Revenue | NT$588.96m |
Gross Profit | NT$239.54m |
Other Expenses | NT$153.83m |
Earnings | NT$85.71m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 1.62 |
Gross Margin | 28.91% |
Net Profit Margin | 10.35% |
Debt/Equity Ratio | 56.3% |
How did 4161 perform over the long term?
See historical performance and comparison